{
    "title": "Electromagnetic Treatment of Cancer",
    "inventor_name": "Boris Pasche",
    "publication_year": 2012,
    "device_name": "Low-Energy Modulated Electromagnetic Therapy System",
    "goal": "Inhibit or halt the growth of cancer cells using low-intensity, amplitude-modulated electromagnetic fields.",
    "problem_addressed": "Uncontrolled proliferation of cancer cells and limited effectiveness of existing therapies.",
    "concept_summary": "A low-intensity electromagnetic field, delivered via a spoon-shaped mouth antenna, is amplitude-modulated at precise frequencies (0.1 Hz-50 kHz). The device's microprocessor controls carrier frequency and modulation frequency with high accuracy, producing emissions that selectively affect cancer cells while sparing healthy tissue.",
    "detailed_description": "The patented system comprises controllable low-energy high-frequency carrier generators, amplitude-modulation control generators, and programmable modulation-frequency control generators. A microprocessor or integrated circuit receives control data and drives the generators. The emissions are coupled to an electrically conductive applicator (e.g., a mouth-placed probe) via an impedance transformer to match patient load. Clinical trials reported in the British Journal of Cancer used the device three times daily on patients with advanced liver cancer, resulting in tumor shrinkage and long-term survival for a small subset of participants. Laboratory studies suggest the fields interfere with gene activity in cancer cells, reducing their ability to divide.",
    "category": "Electromagnetism & Magnetism",
    "principles": [
        "Low-intensity electromagnetic field exposure",
        "Amplitude modulation of carrier signal",
        "Precise frequency control (+/-0.001 Hz)",
        "Electronic control via microprocessor"
    ],
    "scientific_domains": [
        "Medicine",
        "Oncology",
        "Bioelectromagnetics",
        "Electrical Engineering"
    ],
    "mechanisms_of_action": [
        "Modulation of gene expression in cancer cells",
        "Disruption of cellular signaling pathways",
        "Inhibition of cell division and proliferation"
    ],
    "materials": [
        "Copper (antenna conductors)",
        "Silicon (integrated circuits)",
        "Plastic (device housing)",
        "Battery (electrical power source)"
    ],
    "energy_sources": [
        "Electrical power (battery or external supply)"
    ],
    "inputs": [
        "Control information (frequency settings)",
        "Electrical power"
    ],
    "outputs": [
        "Amplitude-modulated low-energy electromagnetic emissions",
        "Therapeutic effect (cancer cell inhibition)"
    ],
    "claimed_performance": "Tumour shrinkage and long-term survival observed in a small number of advanced liver cancer patients during three-times-daily treatment.",
    "experimental_evidence": "Clinical trials reported in the British Journal of Cancer (2012) with advanced liver cancer patients; laboratory cell-culture experiments showing frequency-dependent growth inhibition.",
    "replication_status": "Early-stage clinical trials; further large-scale studies required; no commercial deployment reported.",
    "keywords": [
        "low-intensity electromagnetic field",
        "cancer therapy",
        "amplitude modulation",
        "frequency control",
        "bioelectromagnetics",
        "clinical trial"
    ],
    "related_technologies": [
        "Low-Energy Emission Therapy (LEET)",
        "NovoCure implantable electrode technology",
        "Bioelectromagnetic medicine"
    ],
    "controversy_level": "medium",
    "confidence_score": 0.85,
    "practicability_score": 0.6,
    "fringe_score": 0.4,
    "evidence_strength": 0.5,
    "risk_score": 0.2,
    "trl_estimate": 4,
    "source_urls": [
        "http://www.guardian.co.uk/science/2012/jan/08/electromagnetic-fields-could-stop-cancer",
        "https://patents.google.com/patent/EP1974769A1",
        "https://patents.google.com/patent/MX2009010425A"
    ],
    "organizations": [
        "University of Alabama, Birmingham",
        "US Food and Drug Administration (FDA) - trial permission"
    ],
    "applications": [
        "Cancer treatment (primary)",
        "Potential adjunct to existing oncological therapies"
    ],
    "limitations": [
        "Very small patient cohort; statistical significance unclear",
        "Mechanism of action not fully elucidated",
        "Device requires precise frequency control and patient-specific calibration"
    ],
    "open_questions": [
        "What are the optimal frequencies for different cancer types?",
        "How does the field interact at the molecular level with cancer cell DNA?",
        "What are the long-term safety implications of repeated exposure?"
    ],
    "red_flags": [
        "Lack of large-scale, peer-reviewed clinical data",
        "Potential over-statement of efficacy based on limited trials"
    ],
    "evidence_quotes": [
        "Patients hold a spoon-shaped antenna in their mouths to deliver a very low-intensity electromagnetic field in their bodies.",
        "In trials of patients with advanced liver cancer, the therapy given three times a day resulted in long-term survival for a small number of those monitored.",
        "Low-level electromagnetic fields interfere with the activity of genes in cancer cells, affecting their ability to grow and divide.",
        "The intensity of the fields used were between 100 and 1,000 times lower than those from a mobile phone.",
        "The system comprises one or more controllable low-energy high-frequency carrier signal generator circuits with amplitude-modulation control."
    ]
}